$ZTS News
Last published 13h ago
- 13h agoZTSZoetis Receives USDA License for Cytopoint Plus™: The First and Only Long-Acting Monoclonal Antibody Providing 75 Days of Allergic Itch Relief in Dogs with Allergic DermatitisBusiness WirePARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Cytopoint Plus is the first and only USDA-licensed next-generation mAb that provides 75 days of allergic itch relief in a single injection.
- 1d agoZTSZoetis to Participate in the Jefferies Global Healthcare Conference in LondonBusiness WirePARSIPPANY, N.J.--(BUSINESS WIRE)---- $ZTS #animalhealth--Zoetis Inc. (NYSE:ZTS) today announced that Jay Saccaro, EVP, Chief Financial Officer and Chief Operating Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on Monday, November 16, 2026 at 2 p.m. GMT. Interested parties can access the live webcast of the presentation by visiting https://inve ...
- 6d agoZTSZoetis Quarterly Corporate Performance - Third Quarter 2026 - ZOETIS INCEarnings Call TranscriptsWelcome to the third quarter 2026 Financial Results Conference Call and a webcast for Zoetis. Hosting the call today is Matthew Osermeyer, Senior Vice President, Corporate Finance for ZoETIS. Presentation materials and a
- 6d agoZTSZoetis Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 3w agoZTSZoetis Receives FDA Approval for Convenia® RTU for Dogs (cefovecin injectable suspension), Helping More Medium and Large Dogs Access Single-Injection TreatmentBusiness WireConvenia RTU for Dogs can provide up to 14 days of antibiotic treatment of susceptible bacterial skin infections in dogs in a single injection by a veterinary professional Pyoderma – a bacterial skin infection—is
- 4w agoZTSZoetis Appoints Iris Knobloch to its Board of DirectorsBusiness WireKnobloch brings deep expertise in consumer strategy, digital transformation, international leadership, and global board experience to the Zoetis Board Zoetis Inc. (NYSE:ZTS) today announced the appointment of Iris
- 1mo agoZTSZoetis Declares Fourth Quarter 2026 DividendBusiness WireThe Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.53 per share for the fourth quarter of 2026. The dividend will be paid on Tuesday, December 1, 2026, to all holders of record of the
- 1mo agoZTSNew Peer-Reviewed Publication on Laboratory Study That Demonstrated Simparica Trio® Protected 3x More Dogs From Infection With a Resistant Heartworm Isolate Than NexGard® Plus1Business WireFindings highlight dose-dependent efficacy of moxidectin in preventing heartworm disease Published Data Demonstrated: Simparica Trio®-treated dogs had significantly lower average heartworm counts than NexGard
- 1mo agoZTSZoetis to Host Webcast and Conference Call on Third Quarter 2026 Financial ResultsBusiness WireZoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, November 5, 2026. Chief Executive Officer Kristin Peck and Executive Vice President, Chief Financial Officer and Chief
- 1mo agoZTSMorgan Stanley 24th Annual Global Healthcare Conference - ZOETIS INCEarnings Call TranscriptsGood afternoon, everyone. My name is Erin Wright. I'm the Lead Healthcare Services Analyst at Morgan Stanley. We're happy to have Duettis with us today, but first, for more important disclosures, please see the Morgan St
- 2mo agoZTSZoetis to Participate in the Morgan Stanley 24th Annual Global Healthcare ConferenceBusiness WireZoetis Inc. (NYSE:ZTS) today announced that Kristin Peck, Chief Executive Officer, and Jay Saccaro, EVP, Chief Financial Officer and Chief Operating Officer, will participate in a fireside chat at the Morgan Stanley
- 3mo agoZTSZoetis Receives Emergency Use Authorization for Simparica Trio® (sarolaner, moxidectin, and pyrantel chewable tablets) for Treatment of New World Screwworm Infestations in Dogs and PuppiesBusiness WireExpands the solutions available to veterinarians to help address New World screwworm and gives added confidence for pet owners whose dogs and puppies are already receiving Simparica Trio Milestone demonstrates
- 3mo agoZTSZoetis Appoints Jay Saccaro as Chief Financial Officer and Chief Operating OfficerBusiness WireSaccaro’s Appointment is Effective August 17, 2026; Wetteny Joseph to Serve as a Special Advisor to the CEO on Financial Matters Until Early 2027 Zoetis Inc. (NYSE:ZTS) today announced the appointment of James (Jay)
- 3mo agoZTSZoetis Announces Second Quarter 2026 ResultsBusiness WireRevenue Flat at $2.5 Billion and Net Income of $691 Million, or $1.65 per Diluted Share, Decreasing 5% and Increasing 1%, Respectively, on a Reported Basis Adjusted Net Income of $781 Million, or Adjusted Diluted
- 3mo agoZTSZoetis Launches Portela® (relfovetmab) in Canada and the European UnionBusiness WireFirst long-acting anti-NGF monoclonal antibody therapy for cats offers three months of osteoarthritis pain relief with a single injection Zoetis Inc. (NYSE:ZTS) today announced the commercial launch of Portela®
- 3mo agoNES.N-CHNVOLLYCL+5Fat cat? Weight-loss drugs may be coming for your overweight petCNBCStartups are testing GLP-1 treatments for overweight cats while pet-food giants are leaning into longevity products as owners spend more on animal health.
- 3mo agoZTSSueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of July 27, 2026 in Zoetis Inc. Lawsuit - ZTSPR NewswireSell-side coverage of Zoetis Inc. (NYSE: ZTS) shifted dramatically over a nine-month span successive revelations forced analysts to reprice the...
- 3mo agoZTSZoetis Launches Lenivia® (izenivetmab injection) in Canada and the European UnionBusiness WireUp to 40% of dogs may have radiographic osteoarthritis - New long-acting monoclonal antibody therapy offers three months of osteoarthritis pain relief for dogs with a single injection Zoetis Inc. (NYSE:ZTS) today
- 4mo agoZTSZoetis Announces Agreement to Acquire VitalRADS, Accelerating Diagnostic CapabilitiesBusiness WireAcquisition would strengthen Zoetis’ Global Diagnostics portfolio through teleradiology, imaging services, and workflow technology, advancing a more comprehensive end-to-end Virtual Reference Lab Zoetis Inc. today
- 4mo agoZTSZoetis Receives European Commission Marketing Authorization for Poulvac® Procerta® HVT-NDBusiness WireRecombinant vector vaccine protects chickens against Newcastle disease and Marek's disease in a single dose Zoetis Inc. (NYSE:ZTS) today announced that the European Commission (EC) has granted marketing
- 4mo agoZTSZoetis to Host Webcast and Conference Call on Second Quarter 2026 Financial ResultsBusiness WireZoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, August 6, 2026. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph
- 5mo agoLULU.SPX.DJI.IXIC+4May jobs report, Quantinuum's IPO, a record-setting season on Broadway and more in Morning SquawkCNBCHere are five key things investors need to know to start the trading day.
- 5mo agoZTSZoetis Releases 2025 Sustainability Report: Advancing Sustainability in Animal Health for a Better FutureBusiness WireAchieved initial targets set in 2021 across Communities, Animals and Planet $35 million in grants disbursed by the Zoetis Foundation from 2021-2025 Received regulatory approvals for innovative vaccines and
- 5mo agoZTSZoetis to Participate in Upcoming Investor ConferencesBusiness WireZoetis Inc. (NYSE:ZTS) today announced that a representative of the company will participate in fireside chats at the following investor conferences. Stifel 2026 Jaws & Paws Conference on Thursday, May 28, 2026
- 5mo agoZTSZoetis Declares Third Quarter 2026 DividendBusiness WireThe Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.53 per share for the third quarter of 2026. The dividend will be paid on Tuesday, September 1, 2026, to all holders of record of the
- 6mo agoZTSZoetis Announces First Quarter 2026 ResultsBusiness WireRevenue of $2.3 Billion, Growing 3%, and Net Income of $601 Million, or $1.42 per Diluted Share, Flat and Increasing 6%, Respectively, on a Reported Basis Adjusted Net Income of $646 Million, or Adjusted Diluted EPS
- 7mo agoZTSZoetis to Host Webcast and Conference Call on First Quarter 2026 Financial ResultsBusiness WireZoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, May 7, 2026. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny Joseph
- 8mo agoZTSZoetis to Participate in the KeyBanc Capital Markets Healthcare ForumBusiness WireZoetis Inc. (NYSE:ZTS) today announced that Kristin Peck, Chief Executive Officer, will participate in a fireside chat at the KeyBanc Capital Markets Healthcare Forum on Tuesday, March 17, 2026 at 10:30 a.m.
- 8mo agoZTSZoetis to Participate in Upcoming Investor ConferencesBusiness WireZoetis Inc. (NYSE:ZTS) today announced that Wetteny Joseph, Executive Vice President and Chief Financial Officer, will participate in fireside chats at the following investor conferences. Leerink Global Healthcare
- 8mo agoNEOGZTSZoetis to Acquire Animal Genomics Business from Neogen®, Accelerating Precision Animal Health InnovationBusiness WireAcquisition strengthens Zoetis' leadership in Precision Animal Health by integrating Neogen's global genomics capabilities, expanding predictive insights and individualized care worldwide Zoetis Inc. (NYSE:ZTS) the
- 8mo agoZTSZoetis to Participate in the Bank of America Securities 2026 Animal Health SummitBusiness WireZoetis Inc. (NYSE:ZTS) will participate in the Bank of America Securities 2026 Animal Health Summit on Thursday, February 26, 2026 at 1:15 p.m. ET. Wetteny Joseph, Executive Vice President and Chief Financial Officer,
- 9mo agoZTSZoetis Reports Fourth Quarter and Full Year 2025 ResultsBusiness WireReports Revenue of $2.4 Billion, Growing 3%, and Net Income of $603 Million, or $1.37 per Diluted Share, Increasing 4% and 6%, Respectively, on a Reported Basis for Fourth Quarter 2025 Delivers 4% Organic Operational
- 9mo agoZTSZoetis Declares Second Quarter 2026 DividendBusiness WireThe Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.53 per share for the second quarter of 2026. The dividend will be paid on Tuesday, June 2, 2026, to all holders of record of the Company's
- 10mo agoZTSZoetis to Host Webcast and Conference Call on Fourth Quarter and Full Year 2025 Financial ResultsBusiness WireZoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, February 12, 2026. Chief Executive Officer Kristin Peck and Executive Vice President and Chief Financial Officer Wetteny
- 10mo agoZTSZoetis to Participate in the 44th Annual J.P. Morgan Healthcare ConferenceBusiness WireZoetis Inc. (NYSE:ZTS) will participate in the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026. Kristin Peck, Chief Executive Officer, and Wetteny Joseph, Executive Vice President and Chief
- 11mo agoZTSZoetis Announces Pricing of $1.75 Billion Convertible Senior Notes OfferingBusiness WireSubstantially All of Net Proceeds Expected to Be Used to Repurchase Approximately $1.6 Billion of Common Stock and for Capped Call Transactions Zoetis Inc. (NYSE:ZTS) (the "Company" or "Zoetis") today announced that it
- 11mo agoZTSZoetis Announces Proposed $1.75 Billion Convertible Senior Notes OfferingBusiness WireSubstantially All Net Proceeds Expected to Be Used to Repurchase Common Stock and for Capped Call Transactions Zoetis Inc. (NYSE:ZTS) (the "Company" or "Zoetis") today announced that, subject to market conditions, it
- 11mo agoZTSZoetis Declares First Quarter 2026 Dividend; Board Approves 6% Payment IncreaseBusiness WireThe Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.53 per share for the first quarter of 2026, an increase of 6% from the quarterly dividend rate paid in 2025. The dividend will be paid on
- 11mo agoZTSZoetis Receives Health Canada Approval for Portela™(relfovetmab injection) to Alleviate Pain Associated with Osteoarthritis in CatsBusiness WireZoetis Inc. today announced that Health Canada has approved Portela™ (relfovetmab injection) for the alleviation of pain associated with osteoarthritis (OA) in cats. Designed to provide three months of OA pain
- 11mo agoZTSZoetis Highlights R&D Leadership and Long-Term Growth Opportunity at Innovation WebcastBusiness WireUnderscores Proven Innovation Model, Robust and Diversified Pipeline with 12 Potential Blockbuster1 Candidates, and Unmatched Scale and Capabilities Animal Health Leader Positioned to Deliver Sustained Revenue Growth,
- 11mo agoZTSZoetis Receives European Commission Marketing Authorization for Lenivia® (izenivetmab) to Reduce Pain Associated with Osteoarthritis (OA) in DogsBusiness WireZoetis Inc. today announced that the European Commission has granted the company marketing authorization for Lenivia® (izenivetmab) for the reduction of pain associated with osteoarthritis (OA) in dogs. Lenivia is
- 11mo agoZTSZoetis to Participate in the Piper Sandler 37th Annual Healthcare ConferenceBusiness WireZoetis Inc. (NYSE:ZTS) will participate in the Piper Sandler 37th Annual Healthcare Conference on Thursday, December 4, 2025 at 9:30 a.m. ET. Kristin Peck, Chief Executive Officer and Wetteny Joseph, Executive Vice
- 11mo agoZTSZoetis to Host Innovation WebcastBusiness WireZoetis Inc. (NYSE:ZTS) will host an Innovation Webcast at 8:30 a.m. ET on Tuesday, December 2, 2025, featuring Kristin Peck, Chief Executive Officer; Wetteny Joseph, Executive Vice President and Chief Financial Officer;
- 1y agoZTSZoetis Announces Third Quarter 2025 ResultsBusiness WireReports Revenue of $2.4 Billion, Growing 1%, and Net Income of $721 Million, or $1.63 per Diluted Share, Increasing 6% and 9%, Respectively, on a Reported Basis for Third Quarter 2025 Delivers 4% Organic Operational
- 1y agoZTSZoetis Announces Retirement of Rob Polzer at the End of 2025 and the Appointment of Kevin Esch as President of Research & Development for World Leader in Animal Health Beginning in 2026Business WireDr. Rob Polzer to Retire at the End of the Year After 10-Year Distinguished Career of Advancing Veterinary Medicine and Innovation Zoetis Inc. (NYSE:ZTS) today announced that following a 10-year distinguished career
- 1y agoZTSZoetis Receives European Commission Marketing Authorization for Portela® (relfovetmab) to Alleviate Pain Associated with Osteoarthritis in CatsBusiness WireZoetis Inc. today announced that the European Commission has granted the company marketing authorization for Portela® (relfovetmab), making it the first monoclonal antibody (mAb) therapy with a three-month dosing
- 1y agoZTSZoetis Appoints Stephanie Tilenius to its Board of DirectorsBusiness WireHealth entrepreneur brings her digital and artificial intelligence (AI) experience to Zoetis Board Zoetis Inc. (NYSE:ZTS) today announced the appointment of Stephanie Tilenius to its Board of Directors, effective as
- 1y agoZTSZoetis Announces Health Canada Approval of Lenivia® (izenivetmab injection) for Alleviation of Osteoarthritis (OA) Pain in DogsBusiness WireFirst long-acting canine anti-nerve growth factor monoclonal antibody therapy administered once every three months Approval marks major milestone in the company's continued innovation for canine OA pain Zoetis
- 1y agoZTSZoetis Receives Positive Opinion from CVMP for Lenivia® (izenivetmab) to Reduce Pain Associated with Osteoarthritis (OA) in DogsBusiness WireZoetis Inc. today announced that the Committee for Veterinary Medicinal Products (CVMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of marketing authorization for
- 1y agoZTSZoetis Declares Fourth Quarter 2025 DividendBusiness WireThe Board of Directors of Zoetis Inc. (NYSE:ZTS) has declared a dividend of $0.50 per share for the fourth quarter of 2025. The dividend will be paid on Tuesday, December 2, 2025, to all holders of record of the